Laurent Eckert’s scientific contributions

... The current prevalence in these populations thus ranges from 3% to 20%. 1 Patients with AD and their families suffer a great impact on their quality of life, which worsens as the severity of AD increases, due to factors such as constant itching, loss of sleep, lesions, or associated comorbidities. 2 Therapeutic alternatives in patients with these characteristics, who need long-term systemic treatment, were scarce until the approval of dupilumab, due to the potential adverse effects of classical systemic agents and their off-label use in this population. 3 Dupilumab is a human monoclonal antibody directed against interleukin (IL)-4 receptor alpha, inhibiting IL-4 and IL-13 signalling, 4 and is now licensed in many countries for AD from 6 months of age. ...

Reference:

Real‐life retrospective multicentre study to describe the use of dupilumab in paediatric patients with atopic dermatitis in Spain: Patient profile, effectiveness and safety